GNLX
Genelux Corporation$2.92+0.03 (+1.04%)Prev Close$2.89·MCap$106.5M·P/E—·Vol156.7K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
14
$167.6K
◆
Net Activity
Net Seller
$167.6K
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at Genelux Corporation (GNLX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 14 insider sales totaling $167.6K. The most recent insider transaction was by Smither John W (director), who sold $34.9K worth of shares on Jul 2, 2026. Genelux Corporation operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $106.5M.
GNLX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Smither John W | director | Sell | 12,000 | $2.91 | $34.9K | 91,403 |
| Jun 4, 2026 | Smalling Ralph | officer: Head of Regulatory | Sell | 192 | $2.93 | $562.56 | 67,611 |
| Jun 2, 2026 | Thomas John | director | Sell | 10,000 | $2.98 | $29.8K | 472,784 |
| May 12, 2026 | Zindrick Thomas | officer: President and CEO | Sell | 2,798 | $2.94 | $8.2K | 532,051 |
| May 12, 2026 | Cappello Joseph | officer: Chief Technical Officer | Sell | 605 | $2.97 | $1.8K | 154,549 |
| May 12, 2026 | Yu Yong | officer: Chief Scientific Officer | Sell | 605 | $2.97 | $1.8K | 149,706 |
| May 12, 2026 | Smalling Ralph | officer: Head of Regulatory | Sell | 270 | $2.98 | $804.49 | 67,803 |
| Mar 26, 2026 | Cappello Joseph | officer: Chief Technical Officer | Sell | 906 | $2.42 | $2.2K | 155,154 |
| Mar 26, 2026 | Smalling Ralph | officer: Head of Regulatory | Sell | 585 | $2.46 | $1.4K | 68,313 |
| Mar 26, 2026 | Yu Yong | officer: SVP, Clinical Development | Sell | 906 | $2.42 | $2.2K | 144,938 |
| Mar 26, 2026 | Zindrick Thomas | officer: President and CEO | Sell | 3,582 | $2.42 | $8.7K | 534,849 |
| Dec 1, 2025 | Thomas John | Director | Sell | 10,000 | $5.00 | $50.0K | 0 |
| Aug 21, 2025 | Cappello Joseph | Chief Technical Officer | Sell | 2,733 | $3.34 | $9.1K | 0 |
| Aug 21, 2025 | Yu Yong | SVP, Clinical Development | Sell | 4,192 | $3.82 | $16.0K | 0 |
| May 12, 2025 | Cappello Joseph | VP, Pharmaceutical Development | Sell | 4,737 | $2.92 | $13.8K | 0 |
| May 12, 2025 | Zindrick Thomas | President and CEO | Sell | 10,764 | $2.92 | $31.4K | 0 |
| Dec 30, 2024 | Tyree James L | Sell | 3,460 | $2.46 | $8.5K | 45,791 | |
| Dec 18, 2024 | Cappello Joseph | VP, Pharmaceutical Development | Sell | 6,300 | $2.34 | $14.7K | 14,653-30% |
| Dec 18, 2024 | Smalling Ralph | Head of Regulatory | Sell | 2,510 | $2.34 | $5.9K | 16,322 |
| Dec 18, 2024 | Zak Lourie S. | Chief Financial Officer | Sell | 2,103 | $2.34 | $4.9K | 40,802 |
| Dec 18, 2024 | Zindrick Thomas | President and CEO | Sell | 14,315 | $2.34 | $33.5K | 37,372-28% |
| Sep 13, 2024 | Szalay Aladar | Sell | 64,857 | $2.65 | $171.7K | 632,901 | |
| Sep 12, 2024 | Tyree James L | Sell | 1,730 | $2.60 | $4.5K | 47,521 | |
| Sep 11, 2024 | Szalay Aladar | Sell | 75,143 | $2.62 | $196.6K | 716,438 | |
| Sep 6, 2024 | Szalay Aladar | Sell | 42,818 | $2.09 | $89.6K | 739,821 | |
| Aug 30, 2024 | Szalay Aladar | Sell | 265,552 | $2.09 | $554.4K0.7% OS | 1,032,273 | |
| Aug 27, 2024 | Szalay Aladar | Sell | 91,630 | $2.19 | $200.3K | 1,099,821 | |
| Jul 8, 2024 | Jewett Caroline | Head of Quality | Sell | 4,961 | $2.12 | $10.5K | 16,174 |
| Jul 8, 2024 | Ryder Sean | General Counsel | Sell | 5,496 | $2.12 | $11.7K | 19,388 |
| Jul 8, 2024 | Yu Yong | VP, Clinical Trial Operations | Sell | 6,849 | $2.12 | $14.5K | 10,869-39% |
| May 15, 2024 | Szalay Aladar | Sell | 35,966 | $3.62 | $130.4K | 1,172,341 | |
| May 9, 2024 | Szalay Aladar | Sell | 19,944 | $3.78 | $75.3K | 1,189,706 | |
| May 1, 2024 | Szalay Aladar | Sell | 59,999 | $3.23 | $193.9K | 1,249,327 | |
| Apr 24, 2024 | Szalay Aladar | Sell | 44,395 | $3.51 | $155.6K | 1,285,794 | |
| Apr 18, 2024 | Szalay Aladar | Sell | 71,420 | $3.59 | $256.2K | 1,322,862 | |
| Dec 18, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 32,535 | $13.16 | $428.2K | 5,803-85% |
| Dec 14, 2023 | Thomas John | Director | Sell | 9,000 | $13.38 | $120.4K | 465,387 |
| Dec 14, 2023 | Tyree James L | Director | Sell | 9,000 | $13.22 | $119.0K | 6,807-57% |
| Dec 8, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 36,800 | $11.85 | $436.0K | 32,535-53% |
| Nov 22, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 18,665 | $10.26 | $191.6K | 69,335 |
| Nov 21, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 18,135 | $11.60 | $210.4K | 102,594 |
| Oct 26, 2023 | Szalay Aladar | 10% Owner | Sell | 5,704 | $19.40 | $110.6K | 1,371,545 |
| Oct 25, 2023 | Szalay Aladar | 10% Owner | Sell | 49,987 | $19.97 | $998.4K | 1,377,249 |
| Oct 25, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 5,200 | $19.11 | $99.4K | 106,135 |
| Oct 16, 2023 | Thomas John | Director | Sell | 3,333 | $20.71 | $69.0K | 473,341 |
| Oct 11, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 5,200 | $22.01 | $114.5K | 106,535 |
| Oct 10, 2023 | Szalay Aladar | 10% Owner | Sell | 14,251 | $24.93 | $355.2K | 1,428,221 |
| Oct 4, 2023 | Szalay Aladar | 10% Owner | Sell | 75,690 | $25.49 | $1.93M | 1,441,487 |
| Sep 29, 2023 | Szalay Aladar | 10% Owner | Sell | 13,546 | $24.41 | $330.7K | 1,519,466 |
| Sep 27, 2023 | Szalay Aladar | 10% Owner | Sell | 42,263 | $24.38 | $1.03M | 1,569,039 |
Showing 1–50 of 71
1 / 2
GNLX Insider Buying Activity
The following table shows recent insider purchases of Genelux Corporation (GNLX) stock reported via SEC Form 4 filings.
No insider buying activity found for GNLX in the last 12 months.
GNLX Insider Selling Activity
The following table shows recent insider sales of Genelux Corporation (GNLX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Smither John W | director | Sell | 12,000 | $2.91 | $34.9K | 91,403 |
| Jun 4, 2026 | Smalling Ralph | officer: Head of Regulatory | Sell | 192 | $2.93 | $562.56 | 67,611 |
| Jun 2, 2026 | Thomas John | director | Sell | 10,000 | $2.98 | $29.8K | 472,784 |
| May 12, 2026 | Zindrick Thomas | officer: President and CEO | Sell | 2,798 | $2.94 | $8.2K | 532,051 |
| May 12, 2026 | Cappello Joseph | officer: Chief Technical Officer | Sell | 605 | $2.97 | $1.8K | 154,549 |
| May 12, 2026 | Yu Yong | officer: Chief Scientific Officer | Sell | 605 | $2.97 | $1.8K | 149,706 |
| May 12, 2026 | Smalling Ralph | officer: Head of Regulatory | Sell | 270 | $2.98 | $804.49 | 67,803 |
| Mar 26, 2026 | Cappello Joseph | officer: Chief Technical Officer | Sell | 906 | $2.42 | $2.2K | 155,154 |
| Mar 26, 2026 | Smalling Ralph | officer: Head of Regulatory | Sell | 585 | $2.46 | $1.4K | 68,313 |
| Mar 26, 2026 | Yu Yong | officer: SVP, Clinical Development | Sell | 906 | $2.42 | $2.2K | 144,938 |
| Mar 26, 2026 | Zindrick Thomas | officer: President and CEO | Sell | 3,582 | $2.42 | $8.7K | 534,849 |
| Dec 1, 2025 | Thomas John | Director | Sell | 10,000 | $5.00 | $50.0K | 0 |
| Aug 21, 2025 | Cappello Joseph | Chief Technical Officer | Sell | 2,733 | $3.34 | $9.1K | 0 |
| Aug 21, 2025 | Yu Yong | SVP, Clinical Development | Sell | 4,192 | $3.82 | $16.0K | 0 |
| May 12, 2025 | Cappello Joseph | VP, Pharmaceutical Development | Sell | 4,737 | $2.92 | $13.8K | 0 |
| May 12, 2025 | Zindrick Thomas | President and CEO | Sell | 10,764 | $2.92 | $31.4K | 0 |
| Dec 30, 2024 | Tyree James L | Sell | 3,460 | $2.46 | $8.5K | 45,791 | |
| Dec 18, 2024 | Cappello Joseph | VP, Pharmaceutical Development | Sell | 6,300 | $2.34 | $14.7K | 14,653-30% |
| Dec 18, 2024 | Smalling Ralph | Head of Regulatory | Sell | 2,510 | $2.34 | $5.9K | 16,322 |
| Dec 18, 2024 | Zak Lourie S. | Chief Financial Officer | Sell | 2,103 | $2.34 | $4.9K | 40,802 |
| Dec 18, 2024 | Zindrick Thomas | President and CEO | Sell | 14,315 | $2.34 | $33.5K | 37,372-28% |
| Sep 13, 2024 | Szalay Aladar | Sell | 64,857 | $2.65 | $171.7K | 632,901 | |
| Sep 12, 2024 | Tyree James L | Sell | 1,730 | $2.60 | $4.5K | 47,521 | |
| Sep 11, 2024 | Szalay Aladar | Sell | 75,143 | $2.62 | $196.6K | 716,438 | |
| Sep 6, 2024 | Szalay Aladar | Sell | 42,818 | $2.09 | $89.6K | 739,821 | |
| Aug 30, 2024 | Szalay Aladar | Sell | 265,552 | $2.09 | $554.4K0.7% OS | 1,032,273 | |
| Aug 27, 2024 | Szalay Aladar | Sell | 91,630 | $2.19 | $200.3K | 1,099,821 | |
| Jul 8, 2024 | Jewett Caroline | Head of Quality | Sell | 4,961 | $2.12 | $10.5K | 16,174 |
| Jul 8, 2024 | Ryder Sean | General Counsel | Sell | 5,496 | $2.12 | $11.7K | 19,388 |
| Jul 8, 2024 | Yu Yong | VP, Clinical Trial Operations | Sell | 6,849 | $2.12 | $14.5K | 10,869-39% |
| May 15, 2024 | Szalay Aladar | Sell | 35,966 | $3.62 | $130.4K | 1,172,341 | |
| May 9, 2024 | Szalay Aladar | Sell | 19,944 | $3.78 | $75.3K | 1,189,706 | |
| May 1, 2024 | Szalay Aladar | Sell | 59,999 | $3.23 | $193.9K | 1,249,327 | |
| Apr 24, 2024 | Szalay Aladar | Sell | 44,395 | $3.51 | $155.6K | 1,285,794 | |
| Apr 18, 2024 | Szalay Aladar | Sell | 71,420 | $3.59 | $256.2K | 1,322,862 | |
| Dec 18, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 32,535 | $13.16 | $428.2K | 5,803-85% |
| Dec 14, 2023 | Thomas John | Director | Sell | 9,000 | $13.38 | $120.4K | 465,387 |
| Dec 14, 2023 | Tyree James L | Director | Sell | 9,000 | $13.22 | $119.0K | 6,807-57% |
| Dec 8, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 36,800 | $11.85 | $436.0K | 32,535-53% |
| Nov 22, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 18,665 | $10.26 | $191.6K | 69,335 |
| Nov 21, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 18,135 | $11.60 | $210.4K | 102,594 |
| Oct 26, 2023 | Szalay Aladar | 10% Owner | Sell | 5,704 | $19.40 | $110.6K | 1,371,545 |
| Oct 25, 2023 | Szalay Aladar | 10% Owner | Sell | 49,987 | $19.97 | $998.4K | 1,377,249 |
| Oct 25, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 5,200 | $19.11 | $99.4K | 106,135 |
| Oct 16, 2023 | Thomas John | Director | Sell | 3,333 | $20.71 | $69.0K | 473,341 |
| Oct 11, 2023 | Yu Yong | VP, Clinical Trial Operations | Sell | 5,200 | $22.01 | $114.5K | 106,535 |
| Oct 10, 2023 | Szalay Aladar | 10% Owner | Sell | 14,251 | $24.93 | $355.2K | 1,428,221 |
| Oct 4, 2023 | Szalay Aladar | 10% Owner | Sell | 75,690 | $25.49 | $1.93M | 1,441,487 |
| Sep 29, 2023 | Szalay Aladar | 10% Owner | Sell | 13,546 | $24.41 | $330.7K | 1,519,466 |
| Sep 27, 2023 | Szalay Aladar | 10% Owner | Sell | 42,263 | $24.38 | $1.03M | 1,569,039 |
GNLX Insiders
Similar Stocks to GNLX
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B